Beyond Biotech - the podcast from Labiotech

Labiotech
  • 3.0（2則評分）
  • 科技新聞
  • 每週更新
Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.

  1. 2 天前

    Biotech beyond earth: The future of medicine in space

    LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease.Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural NASA Space-H Accelerator program, and how medicine can support human deep-space missions.LinkGevity was selected for the program, which is in its ina...

    39 分鐘

  2. 10月18日

    The future of gene therapy

    Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. Spur Therapeutics is a clinical-stage biotech company dedicated to developing next generation gene therapies for people living with chronic, debilitating diseases. Its lead candidate, FLT201, is an AAV gene therapy for Gaucher...

    33 分鐘

  3. 10月11日

    Bispecific ADCs: the next generation of cancer treatments

    Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge.Some biopharma companies are investing in what they hope will be the next-generation approach to ADCs – bispecific ADCs. More than a dozen early-stage clinical trials are evaluating whether adding a second targeting functionality can improve the preciseness...

    30 分鐘

  4. 10月4日

    Targeting telomerase to disrupt cancer

    Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosomes, and it is reactivated in most cancers. Most human tumors not only express telomerase but also have very short telomeres. This makes telomerase a prime target for cancer therapies. MAIA Biotechnology is focused on the pioneering approach of telomere targeting ...

    27 分鐘

  5. 9月27日

    Harnessing the body’s natural targeted protein degradation system to treat diseases

    C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-stage biopharmaceutical company is dedicated to creating a new generation of medicines using its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. TORPEDO can design molecular glues and heterobifunction...

    34 分鐘

  6. 9月20日

    Estonia's biobank: Is this the first large-scale personalized medicine initiative?

    Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank.The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adaptation of public health systems. The Estonian Biobank has samples from 20% of the adult population; in comparison, UK biobanks only represent 0.7% of the population. With so much data, Estonia can determine risk factors for cancer, cardiovascular disease, ...

    32 分鐘

  7. 9月13日

    Targeting inflammation: A revolution in disease treatment

    Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies including fibrotic, dermatological, rheumatological diseases as well as neurological disorders such as Alzheimer’s disease.Halia Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to...

    43 分鐘

  8. 9月6日

    The power of tumor infiltrating lymphocytes to fight melanoma

    Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline.Iovance recently submitted a marketing authorization application to the European Medicines Agency for lifileucel, a TIL cell therapy, for the treatment of adult patients with un...

    38 分鐘
顯示全部 (120)

評分與評論

3
（滿分 5 顆星）
2 則評分

簡介

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.

資訊

你可能也會喜歡

若要收聽兒少不宜的單集，請登入帳號。

隨時掌握此節目最新消息

登入或註冊後，即可追蹤節目、儲存單集和掌握最新資訊。
選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大